reason report
inclisiran lesson fourier/odyssey may better
trojan hors
bottom line see odyssey outcom updat
american colleg cardiolog meet de-risk
mdco inclisiran hypercholesterolemia tackl two
controversi head-on first data valid long-
term benefit reduc low-dens lipoprotein cholesterol ldl-
 second mechan inhibit proprotein convertas
subtilisin/kexin type one pursu inclisiran
effect ldl-lower pt outcom commerci
front intrigu sanofi/regeneron plan increas pt
access praluent investor cautiou market
respons lacklust repatha mp praluent sale
howev sny/regn op op initi may unveil true market
oppti drug thaw investor skeptic inclisiran
progress later stage clinic develop
reiter op mdco
odyssey reduct ldl-c major advers cardiac event
mace primari endpoint all-caus mortal favor
safeti profil briefli intent-to-treat basi praluent reduc
ldl-c baselin translat reduct mace
hr all-caus mortal hr
sub-group analysi higher baselin ldl-c pt mg/dl
howev pronounc benefit mace hr mortal
hr observ time imbal
praluent pbo cohort sum odyssey
fourier result support hypothesi ldl-c lower confer
long-term cardiovascular benefit despit differ chemic
composit rnai inclisiran vs antibodi repatha/pralu
view posit result two larg outcom data de-risk
thank fourier odyssey inclisiran outcom data
like mirror improv upon predecessor view
mdco follow statu huge advantag prior initi
outcom trial mdco leverag lesson two
prior cvot studi fact mdco alreadi recruit lead kol
steer committe outcom studi dr marc sabatin
eugen braunwald fourier greg schwartz odyssey rori
reveal john kastelein trial protocol
final remain confid mdco balanc recruit speed
qualiti pt cost trial start management initi pt pre-
identif use uk nh electron on-line record expect
front-end load rapid enrol similar trial link link
target baselin ldl-c mg/dl maintain follow-up
durat yr maxim odd demonstr mortal
benefit mdco truli stand shoulder giant could
materi result better odyssey
market stupid sny/regn attent pt access/
afford could expand market ahead inclisiran
pleas refer page import disclosur price chart analyst certif
launch judg sale drug
repatha/pralu investor caution market seem warrant
justifi financi impact updat repatha label may
becom clearer come quarter think sny/regn initi
tailwind inclisiran two way priorit value-
base price simultan improv pt access expand
market beyond sale figur might suggest contrari
net neg impact praluent gross margin inclisiran
unpreced price flexibl match competit price
praluent note adjust odyssey result institut
clinic econom review icer publish updat value-bas
price benchmark praluent rang pt
recent acut coronari event higher risk pt
mg/dl ldl-c annual basi link valu light
mdco intent enrol higher risk pt outcom trial suggest
inclisiran model may conserv end annual net
price peak ww sale consequ
market evolv particular interest
joseph schwartz certifi view express report accur reflect view part
compens directli relat specif recommend view contain report
estim fair valu month mdco share sum-of-the-part dcf analysi includ net
cash overal use wacc discount rate sinc risk involv drug develop regulatori
approv alreadi handicap probability-weight revenu estim pipelin asset appli
termin growth rate continu assum peak vabomer revenu mdco
receiv royalti net sale melinta probability-weight peak inclisiran revenu
risk valuat
risk associ clinic develop commerci activ impact mdco valuat earn power
signific invest necessari develop inclisiran trial delay dilut financ and/or failur deliv
non-dilut financ plan continu weak broader market pose risk
distribut ratings/invest bank servic ib
explan rate
outperform buy expect stock outperform benchmark next month
market perform hold/neutr expect stock perform line benchmark next
under-perform sell expect stock under-perform benchmark next month
degre out-performance under-perform requir warrant outperform under-perform
rate commensur risk profil compani
purpos definit relev benchmark
market capit less billion
capit billion
health index issuer
health index issuer market
inform includ limit price quot statist obtain sourc
believ reliabl repres accur complet reli
upon inform subject chang without notic provid inform purpos
regard offer sell solicit offer buy product
inform relat firm offic director employe proprietari account affili may
posit long short secur refer report and/or relat secur
time time may increas decreas posit express view contrari contain
report firm salespeopl trader profession may provid oral written market
commentari trade strategi contrari opinion express report firm proprietari
account may make invest decis inconsist opinion express report
past perform secur guarante predict futur perform transact strategi
describ herein may suitabl investor addit inform avail upon request
contact editori depart one feder street floor boston
like firm employe analyst receiv compens impact among factor overal firm
profit includ revenu among busi unit institut equiti invest
bank analyst howev compens specif invest bank servic transact
contribut firm invest bank activ
medacorp network healthcar profession attorney physician key opinion leader
specialist access leerink provid inform use analyst prepar research
leerink partner llc make market medicin compani amgen inc
inc sanofi
leerink partner llc will sell buy client common stock sanofi princip basi
leerink place market perform rate novemb
leerink place outperform rate mdco januari
leerink place outperform rate juli
leerink place market perform rate san fp octob
member finra/sipc leerink partner llc right reserv document may reproduc
circul without written author
director equiti research
associ director research
director research
mid- small-cap biotechnolog
